Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093951 · ClinicalTrials.gov registry record · Phase 2
SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)
A Phase 2 study of Alzheimers Disease, sponsored by Saegis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
- 20
- Study locations
NCT00093951: Completed Phase 2 study of Alzheimers Disease, sponsored by Saegis Pharmaceuticals.
NCT00093951 is a Phase 2 study of Alzheimers Disease that has completed, run by Saegis Pharmaceuticals. The registered enrollment target is 280 participants, below the 4,059-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00093951, a Phase 2 study of Alzheimers Disease, has completed, sponsored by Saegis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.
Conditions Studied
Interventions
- DRUG SGS742
Study Locations (20)
California
- Margolin Brain Institute - Fresno
- NervePro Research - Irvine
- Center for Neurologic Studies - La Jolla
- Neuro Therapeutics, Inc. - Pasadena
- Pacific Research Network, Inc. - San Diego
- Affiliated Research Institute - San Diego
- San Francisco Clinical Research Center - San Francisco
- Southern California Clinical Research, Inc. - San Marino
Florida
- Baumel-Eisner Neuromedical Institute, Inc. - Boca Raton
- Bradenton Neurology, Inc. - Bradenton
- Brain Matters, Inc. - Delray Beach
- Baumel-Eisner Neuromedical Institute - Fort Lauderdale
- Berma Research Group - Hialeah
Arizona
- - Phoenix
- Dedicated Clinical Research - Sun City
- Northwest NeuroSpecialists, PLLC - Tucson
Connecticut
- Research Center for Clinical Studies, Inc. - Darien
- - Stamford
Arkansas
- Clinical Trials Incorporated - Little Rock
Colorado
- The Mile High Research Center - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2004-04 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00093951
The ClinicalTrials.gov registry entry for NCT00093951 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,059-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (93% lower). The listed sponsor is Saegis Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which SGS742 is the first listed.
NCT00093951 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00093951 about?
NCT00093951 is a clinical study titled "SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)". The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.
What is the current status of trial NCT00093951?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2004-04. Estimated completion is 2007-09.
What conditions does trial NCT00093951 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT00093951?
The interventions under investigation include: SGS742 (DRUG).
Who is sponsoring clinical trial NCT00093951?
This trial is sponsored by Saegis Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00093951 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.